Centocor's Myoscint adequate in detecting suspected MI, clinical utility unclear -- FDA advisory committee.
CENTOCOR MYOSCINT PERFORMANCE STANDARD ADEQUATE, CLINICAL UTILITY QUESTIONABLE for the detection of myocardial infarction, FDA's Cardiovascular & Renal Drugs Advisory Committee, with representation from the Medical Imaging Drugs Advisory Committee, concluded Jan. 26. The committee voted 8-5 to recommend Myoscint's approval (PLA 95-1210) for imaging in the setting of chest pain suspected to be caused by myocardial infarction.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth